DocPasser

MRCGP Applied Knowledge Test

UK general practice questions sectioned to the RCGP's published AKT blueprint, weighted towards the areas the college's feedback reports keep flagging.

United KingdomRoyal College of General Practitioners written

Coming soon. This bank is still in build and not on sale yet. The banks live now are PLAB 1, MRCP Part 1 and AMC MCQ.

What is on the MRCGP AKT?

Questions or stations160 verified 2026-08-10 Source says: “the number of items in the examination have been reduced from 200 to 160” check it yourself
Time160 minutes verified 2026-08-10 Source says: “the total examination length has been reduced from 190 minutes to 160 minutes” check it yourself
FormatMostly single best answer, with some 'select two' items, free-text answers (drug dose calculations) and extended matching
Adaptive deliveryNo
Pass markStandard set per sitting; the college publishes the pass mark and pass rate with each diet's report. verified 2026-08-10 check it yourself
BlueprintRCGP GP curriculum (2025), Royal College of General Practitioners

From October 2025 the AKT is 160 items in 160 minutes (down from 200 in 190). 128 items are clinical, 16 are evidence-based practice and data interpretation, and 16 are organisation, management and administration.

Verification status. All 3 published figures on this page have been read in the source document and dated above. Source of truth: RCGP GP curriculum (2025), Royal College of General Practitioners. How we verify.

The MRCGP AKT curriculum, section by section

Every question in this bank is tagged to one of the sections below, and the tag traces to RCGP GP curriculum (2025). That is what makes a coverage claim checkable instead of a marketing line. The table shows exactly how many items exist in each section today, including the sections where the answer is none.

Curriculum sectionShare of the blueprintItems in this bank
Cardiovascular health 7% none yet
Metabolic problems and endocrinology 7% 2
Gastroenterology and nutrition 6% none yet
Children and young people 7.5% 51
Mental health, alcohol and substance misuse 6.5% 1
Women's health: gynaecology, pregnancy, contraception and breast 7.5% none yet
Respiratory health 5.5% none yet
Dermatology 4% 25
Ear, nose and throat, speech and hearing 3% 1
Musculoskeletal health 4% none yet
Neurology 4.5% 26
Eyes and vision 3.5% 13
Renal and urology 3% none yet
Men's health 2% none yet
Haematology 2% none yet
Allergy and clinical immunology 1% none yet
Infectious diseases, travel and sexual health 3% none yet
Therapeutics and safe prescribing 1.5% 26
People at the end of life 1.5% 13
Organisation, management and administration 10% 27
Evidence-based practice and data interpretation 10% 26

Coverage today: 11 of 21 sections. We publish the gap rather than hiding it.

Free sample questions

Full explanations for every option, including the ones you didn't pick. The option you nearly chose is usually the one you needed explained. Read these before paying for anything.

A 54-year-old man with type 2 diabetes takes metformin 1 g twice daily. His HbA1c is 62 mmol/mol. He had a myocardial infarction two years ago. His BMI is 33 kg/m² and his eGFR is 74 mL/min/1.73m². According to current NICE guidance, which is the most appropriate addition to his treatment?

  1. A sulfonylurea Wrong. It lowers HbA1c but causes weight gain and hypos, and it does nothing for his heart. After his heart attack he needs the drugs that cut cardiovascular events.
  2. Pioglitazone Wrong. Pioglitazone causes fluid retention and weight gain, and it is avoided in heart failure. NICE now uses it only late, for example when eGFR is below 20 and a DPP-4 inhibitor has failed.
  3. A DPP-4 inhibitor Wrong. A DPP-4 inhibitor has no cardiovascular or renal benefit. NICE keeps it for people whose eGFR is below 30, or for frailty where an SGLT-2 inhibitor is unsafe. Neither applies to him.
  4. An SGLT-2 inhibitor and subcutaneous semaglutide correct Correct. He has atherosclerotic cardiovascular disease (a previous heart attack). NICE NG28 (2026) says offer modified-release metformin, an SGLT-2 inhibitor and semaglutide up to 1 mg weekly, for heart, kidney and sugar benefits.
  5. An SGLT-2 inhibitor alone Wrong. This is half the answer. Since February 2026, NICE says people with atherosclerotic cardiovascular disease should get an SGLT-2 inhibitor and subcutaneous semaglutide on top of metformin.

The point: NICE NG28 changed in February 2026. Most adults with type 2 diabetes now start modified-release metformin and an SGLT-2 inhibitor together. If they have atherosclerotic cardiovascular disease, add subcutaneous semaglutide (up to 1 mg weekly) as well. The heart and kidney protection matters more than the HbA1c here.

Source: NICE NG28: Type 2 diabetes in adults, initial medicines (2026) NICE · tier 1, national regulator or guidance

A patient asks the practice for a copy of their full medical record under UK GDPR. Which is the correct response?

  1. Ask the patient to give a reason before releasing anything Wrong. A person does not have to explain why they want their own data.
  2. Provide the record within 40 days after a £50 fee Wrong. That was the old Data Protection Act 1998 rule. UK GDPR replaced it in 2018.
  3. Provide the record free of charge, normally within one month correct Correct. A subject access request must be answered within one month. It can be extended by two more months if the request is complex. There is no fee unless the request is clearly unfounded or excessive.
  4. Release only the entries the GP thinks are suitable to share Wrong. You can only hold back information that would cause serious harm to the patient or someone else, or that identifies a third party. Each withheld item needs a reason.
  5. Ask the Information Commissioner's Office to approve the release Wrong. The practice is the data controller and answers the request itself. The ICO only gets involved if someone complains.

The point: Subject access request: answer within one month, free of charge, no reason needed. You can extend by two months if it is complex. Remove third-party details and anything likely to cause serious harm, and write down why for each removal.

Source: ICO: Right of access Information Commissioner's Office · tier 1, national regulator or guidance

Where MRCGP AKT sits in the pathway

UK general practice (MRCGP) runs MRCGP AKT → MRCGP SCA. One DocPasser account covers all of them, so moving to the next stage does not mean a new account and a progress history you can no longer see.

MRCGP SCA

Questions people actually ask about MRCGP AKT

What proportion of the AKT is clinical?

80%, which is 128 of the 160 questions. The other 32 are split evenly between evidence-based practice and data interpretation, and organisation, management and administration. The college says these proportions stay the same at every sitting.

How is this bank organised?

By the RCGP's own AKT blueprint. Cardiovascular, endocrine, gastroenterology, children, mental health, women's health and respiratory get the most questions, because the blueprint gives them broader representation. Each section also leans towards the topics the college's feedback reports have flagged over the last two years, such as neurology, prescribing safety, confidentiality, children's acute illness and data interpretation.

Which guidance do the answers follow?

Current UK national guidance. Where the AKT says 'according to national guidance' it means NICE or SIGN, so that is what we cite first. CKS, the BNF, the DVLA, the Green Book and the GMC are used where they are the authority on the point.

Is there an international version?

Yes. MRCGP[INT] is run separately at accredited sites such as South Asia, each with its own local curriculum. The South Asia paper is 200 single best answer questions in three and a half hours, uses NICE for chronic disease and WHO guidance for infectious disease. This bank is written for the UK AKT.

What does MRCGP AKT preparation cost?

MRCGP AKT is a flat £20 for 12 months of access — one price, one purchase, no tiers. The first 10 questions are free, with the full explanation for every option, so you can judge the quality of the explanations before paying for anything.

DocPasser is exam preparation material, not clinical guidance. Nothing here should be used to make a decision about a real patient. Always work from your own local guidelines and seniors.